<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084861</url>
  </required_header>
  <id_info>
    <org_study_id>I.2016.010</org_study_id>
    <nct_id>NCT03084861</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which&#xD;
      42 patients will be enrolled with the principal objective to evaluate the efficacy through&#xD;
      changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal&#xD;
      sensibility, corneal opacity, visual acuity and complications of Neurotrophic Keratopathy&#xD;
      (NK). Patients will be randomized 1:1 to receive experimental treatment (cord blood eye&#xD;
      drops) or conventional treatment (artificial tears and therapeutic contact lens).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which&#xD;
      42 patients will be enrolled with the principal objective to evaluate the efficacy through&#xD;
      changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal&#xD;
      sensibility, corneal opacity, visual acuity and complications of NK. Patients will be&#xD;
      randomized 1:1 to receive experimental treatment (cord blood eye drops) or conventional&#xD;
      treatment (artificial tears and therapeutic contact lens).&#xD;
&#xD;
      All patients, with conventional or experimental treatment, will be treated for 19 days. A&#xD;
      topical antibiotic will be added too as a concomitant treatment to all treatment groups,&#xD;
      until the injury closes or according to medical criteria.&#xD;
&#xD;
      After signing informed consent, inclusion and exclusion criteria will be assessed, and if the&#xD;
      patient meets all the requirements, the patient will be randomized.&#xD;
&#xD;
      After initiation of the treatment, patients will be follow-up at 2-3 days and once a week for&#xD;
      3 weeks. A final follow-up is planned at 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment. No safety issue associated.&#xD;
  </why_stopped>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal lesion size</measure>
    <time_frame>after 3 weeks post-treatment,</time_frame>
    <description>Variation percentage in corneal lesion size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>From date of randomization until the date of the last visit (6 weeks post-treatment)</time_frame>
    <description>Safety evaluation through laboratory data and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal lesion size</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment</time_frame>
    <description>Variation percentage in corneal lesion size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage on the corneal lesion</measure>
    <time_frame>at 3 weeks post-treatment</time_frame>
    <description>Changes stage on the corneal lesion (cured, stage 1, stage 2, stage 3) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative scale of corneal sensibility</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment</time_frame>
    <description>Changes in qualitative scale of corneal sensibility (normoesthesia, hypoesthesia, anesthesia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal opacity</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2, 3 and 6 weeks post-treatment</time_frame>
    <description>Changes on corneal opacity from baseline (not response, improvement, worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>at 2-3 days post-treatment and at 1, 2 and 6 weeks post-treatment</time_frame>
    <description>Line variation in relation to visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotrophic keratopathy</measure>
    <time_frame>From date of randomization until the date of the last visit (6 weeks post-treatment)</time_frame>
    <description>Number of neurotrophic keratopathy complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Neurotrophic Keratopathy</condition>
  <arm_group>
    <arm_group_label>cord blood eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment:&#xD;
Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic&#xD;
Therapeutic Contact lens Description: Air Optix Night&amp;Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cord Blood Eye Drops</intervention_name>
    <description>Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives</description>
    <arm_group_label>cord blood eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Artificial tears: Lubristil ®&#xD;
Therapeutic Contact lens: Air Optix Night&amp;Day</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years old&#xD;
&#xD;
          2. NK stage 2 or 3 (Mackie classification)&#xD;
&#xD;
          3. Signed Informed Consent Form&#xD;
&#xD;
          4. The patient is able to understand the nature of the study and to participate&#xD;
             throughout its duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history of eye tumors&#xD;
&#xD;
          2. Active eye infection&#xD;
&#xD;
          3. Eyelid bad position or eyelid closure problems&#xD;
&#xD;
          4. Conjunctiva scarring&#xD;
&#xD;
          5. Topic chronic eye treatments with corticoids&#xD;
&#xD;
          6. Acute corneal burns (&lt;3 months)&#xD;
&#xD;
          7. Intolerance to contact lens&#xD;
&#xD;
          8. Allergy or inability to receive concomitant treatment with Exocin®&#xD;
&#xD;
          9. Patients with immunosuppressive or chemotherapy treatment&#xD;
&#xD;
         10. Pregnant woman or woman without proper contraceptive methods according to the&#xD;
             investigator (*), or lactating women&#xD;
&#xD;
         11. Participation in another clinical trial in the last month (*) Contraceptive methods&#xD;
             accepted in the protocol are: hormonal, intrauterine device (IUD), barrier methods,&#xD;
             voluntary sterilization or the patient has menopause &gt;1 year duration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergi Querol Giner, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banc de Sang i Teixits</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Quirónsalud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de l'Esperança</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de microcirurgia ocular IMO</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

